A US company has developed a new method for delivering CBD, which it claims makes it up to 20 times more effective. And with ambitions to replace opioids with its cannabis-based treatments, the company is on a mission to create “medicines for the masses”.
US biotech pharma company, Ananda Scientific, claims that its products have some of the highest absorption rates on the market.
With a focus on developing new drug delivery systems, the firm partnered with Hebrew University in Israel to develop a unique technology to deliver CBD into the bloodstream.
Ananda has since designed treatments, that are currently undergoing clinical trials, to alleviate symptoms of specific physical and mental health conditions, including PTSD, anxiety and pain.
The technology is called Nano-Sized Self-Assembled Liquid Structure, a type of droplet designed to enhance bioavailability. Ananda claims that its Liquid Structure CBD is 20 times more bioavailable than standard CBD within the first 30 minutes of administration.
Chief business development officer at Ananda, Mark Coffie, told Cannabis Health: “We own a lot of the cannabinoid intellectual property state out of Hebrew University.
“The company has taken the formulation, the technology, the pedigree of the scientists, the intellectual property and has developed a phenomenal pharmaceutical side to the business.”
Although the vessel is just 15 nanometers in size, Liquid Structure is not classed as nanotechnology, which, according to Coffie, makes the formulation unique.
He explained: “We’re underneath the nanodomain, but what makes us unique is that we are not nanotechnology because we do not manipulate the molecules.
“Other nanotechnologies manipulate, they add hard metals, and particulates – there are particles in nanotechnology, but we have no particulates in our technology, we do not manipulate the CBD at all. That’s what makes us unique.”
Coffie continued: “The bioavailability is the aftermath of the technology, the structure itself. We have a claim on that we’re able to put on the bottle that says we are 20 times more bioavailable than CBD, within the first 30 minutes. Over the time there’s a curve that goes up and back down, but at that peak we like to say it’s 20 times more effective.
“At the end of the day, most people are taking this product to relieve pain, they don’t want to sit around and wait for their medicine to kick in.”
The company also has a nutraceutical arm, which uses the same technologies to produce a product that can be sold over the counter as a food supplement.
“We’ve taken the underlying technology and the intellectual property state, and we’ve passed that down to a nutraceutical side of the business,” Coffie explained.
“We have a pharmaceutical formulation and we have a nutraceutical formulation. Both have the same underlying technologies; both have the same scientists that work on formulations and both have the same intellectual property state behind them. Just the formulation is different from pharma to nutraceutical.”
Rather than sell products under its own name, Ananda partners with consumer CBD brands to get its products on the shelves.
“We look to find brands that can take our assets, data, technology, the technical support, the efficacious applications of ingredient and help develop a product and let them do what they do well, like build a marketing engine and sales engine, because we don’t have that,” Coffie added.
On the pharmaceutical side of the business, Ananda has several clinical trials underway, including two FDA trials and a phase one human clinical trial at the Hadassah Hospital in Israel.
The latter aims to assess the bioavailability and safety of its Liquid Structure CBD formulation. Following the trial’s completion, Ananda intends to move into further human clinical studies to evaluate the efficacy of the technology for treating pain.
This will tie into one of the company’s main missions; to develop a replacement for opioid medications, a leading cause of overdose deaths in North America.
“If we could show that we can provide a cost-effective, non-addictive opioid replacement, I feel like we could save a lot of people’s lives,” Coffie said.
The company recently received approval from the FDA for a second clinical trial evaluating the effect of a unique CBD technology on reducing opioid consumption in chronic pain patients.
Another of the firm’s key focuses is diabetes, a disease that affects 422 million people worldwide according to the World Health Organisation.
Ananda has a number of diabetes trials in progress in the US to test the efficacy of its patented treatment for diabetes. The company hopes that, if approved, the medication will eradicate the negative long term side effects of current diabetes treatment and lower the associated costs.
“The numbers are staggering,” Coffie said.
“Around 40 percent of the world population is pre-diabetic. It could be a rampant disease that could really have a negative impact on humanity worldwide.
“And diabetes treatment is very expensive. Our goal with Ananda is to eradicate poverty by changing healthcare and utilising plant-derived compounds to create real medicines for the masses.”
Leading Ananda is CEO Dr Mark Rosenfeld, former UN adviser to China and pandemic scientist who was responsible for three of four bird flu vaccines. He is also known for discovering the aphrodisiac that enabled the breeding of great pandas in captivity in China.
Working alongside him is the firm’s chief technology officer, Dr Nissim Garti from the Hebrew University in Israel, who sits on the Nobel Peace Prize committee for science.
With an impressive team behind it, the company has ambitious plans, having launched over-the-counter products in the US and the UK through brands such as Brain Body Balance, and plans to expand into the EU, China, Australia and Africa in the near future.
- Malta gives green light to three new cannabis clubs
- European Commission must address ‘inequality’ in access to medicinal cannabis across EU
- 1 in 8 older US adults now use cannabis products, finds study
- 3 main contributors to the entourage effect for cannabis consumers to consider
- Medical cannabis doesn’t impair cognitive function – study
- Ukraine’s medical cannabis legalisation delayed by opponents
- News4 months ago
NHS approves major clinical trial on cannabis medicines and chronic pain
- News6 months ago
UK patient secures first NHS reimbursement for cannabis flowers
- Advocacy6 months ago
Inside a UK cannabis club: changing lives, tackling stigma, building community
- News4 months ago
UK research finds GP support for cannabis as an alternative to opioids for chronic pain
- Industry4 months ago
‘Landmark’ ruling gives hope for UK CBD flower businesses
- News4 months ago
Malta: Advocates emphasise positive effects of cannabis reform amid ‘normalisation’ concerns
- Science4 months ago
Five new cannabis studies – ALS, epilepsy, Parkinson’s, chronic pain and blood pressure
- Science6 months ago
New research suggests alcohol, not cannabis, is the real ‘gateway’ drug